Blog
RSS FeedPosted by Michael Wonder on 02 May 2019
ICER seeks public input for 2020 value assessment framework
2 May 2019 - Accepting Open Input Through 10 June 2019. ...
Posted by Michael Wonder on 02 May 2019
ICER posts draft scoping document for the assessment of treatments for type 2 diabetes mellitus
2 May 2019 - Document open to public comment until 22 May 2019. ...
Posted by Michael Wonder on 23 Apr 2019
ICER's growing impact on drug pricing and reimbursement
17 April 2019 - The Institute for Clinical and Economic Review is sometimes called America's `NICE,’ referring to the National ...
Posted by Michael Wonder on 11 Apr 2019
The perils of value based pricing for prescription drugs
11 April 2019 - How do you determine the value, and the price, of life-saving medication? ...
Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis
11 April 2019 - Document open to public comment until 1 May 2019. ...
Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review to assess treatments for type 2 diabetes mellitus
11 April 2019 - Report will be subject of New England CEPAC meeting in November 2019; open Input now being ...
Posted by Michael Wonder on 09 Apr 2019
Institute for Clinical and Economic Review releases draft evidence report on treatments for peanut allergy
9 April 2019 - Public comment period now open until 8 May 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 07 Apr 2019
Gene therapy was hailed as a revolution. Then came the bill.
7 April 2019 - Cost of new treatments may run into the millions of dollars. ...
Posted by Michael Wonder on 03 Apr 2019
ICER issues final report on Spinraza and Zolgensma, provides policy recommendations related to pricing and coverage of treatments for spinal muscular atrophy
3 April 2019 - Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes ...
Posted by Michael Wonder on 03 Apr 2019
Institute for Clinical and Economic Review Appoints Dr. Pamela Bradt as Chief Scientific Officer
2 April 2019 - The Institute for Clinical and Economic Review has announced the appointment of Pamela Bradt as the organization's ...
Posted by Michael Wonder on 02 Apr 2019
When is the price of a drug unjust? The average lifetime earnings standard
1 April 2019 - The majority of Americans believe that lowering drug prices should be the top health care priority for ...
Posted by Michael Wonder on 26 Mar 2019
Institute for Clinical and Economic Review to assess upadacitinib and other treatments for rheumatoid arthritis
26 March 2019 - Open Input now being accepted; review will be subject to public deliberation at upcoming CTAF meeting. ...
Posted by Michael Wonder on 21 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression
21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 19 Mar 2019
Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils
18 March 2019 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...
Posted by Michael Wonder on 17 Mar 2019
On the use of list prices in drug pricing research
14 March 2019 - In the limitations section of this article, we discussed in detail that list prices do not capture ...